

Singapore's BluMaiden Biosciences appoints new US-based leadership to accelerate global expansion

19 February 2025 | News

Dr Kelly brings 35 years of drug discovery and development experience



BluMaiden Biosciences, a Singapore-based biotech firm, has announced the appointment of Dr Terence Kelly as interim Chief Executive Officer and Professor Damian O'Connell as Chair of the Science Advisory Board and member of the Board of Directors.

Dr Damien Keogh, founder of BluMaiden, will assume the role of Chief Operations Officer, focused on driving the company's scientific, technical, business development, and corporate functions.

Dr. Kelly brings 35 years of drug discovery and development experience. He previously led Boehringer Ingelheim's US medicinal chemistry department and was chief executive officer of CoMentis and Perception Neuroscience, US-based clinical-stage biotech companies focused on neurodegeneration and psychiatric disease. Dr Kelly joined the Board of BluMaiden as a non-executive director in 2021. Throughout his career, he has led teams in medicinal chemistry, high throughput screening, computational chemistry, structural biology, and combinatorial chemistry. Dr Kelly is based in the US and will support the company to build commercial and scientific teams there.

Professor O'Connell has over 25 years' experience in pharma leadership, including roles as SVP and Global Head of Clinical Sciences at Bayer Pharma AG, as well as senior positions at Pfizer, Parke Davis, and Elan Pharmaceuticals. He is currently CEO of the Experimental Drug Development Centre, Singapore's national platform for drug discovery and development, and holds additional positions including Adjunct Professor at the University College Cork, Ireland. Prof. O'Connell will join the Board of BluMaiden as a non-executive director.